Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

By S. Janelidze, N. Mattsson, S. Palmqvist, Ruben Smith, T. Beach, G. Serrano, Xiyun Chai, Nicholas K. Proctor, U. Eichenlaub, Henrik Zetterberg and 5 more. Nature Medicine, 2020

1,061 citations recorded by the source corpus.

Subfields: Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/591ba9cf114aff7814602cec352731c50977f57c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

In Psychiatry and Mental health

Citations in the corpus

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. (2021, positive): “…pTau181’s specificity for Alzheimer’s disease-associated neuropathological changes. pTau181 also differentiated patients with mild cognitive impairment who progressed to Alzheimer’s disease from those who did not progress 39,44,52 and had better performance as a plasma biomarker than did Aβ42/40.”
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021 (2021, positive): “For instance, once approved, blood-based biomarkers could be used to identify patients at risk of developing AD and for monitoring disease progression (33, 34), which would also reduce the current capacity constraints associated with PET imaging (25).”
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup (2024, positive): “75 Thus, some plasma assays, particularly some p-tau217 assays alone or in combination, have accuracy that is equivalent to that of approved CSF assays.”